Home » Lilly Wins Approval for Liver Cancer Treatment
Lilly Wins Approval for Liver Cancer Treatment
May 22, 2019
Eli Lilly has won FDA approval for its Cyramza in liver cancer patients, the first biomarker-driven therapy of its kind.
Cyramza (ramucirumab injection) is approved for patients with hepatocellular carcinoma who have an alpha-fetoprotein (AFP) level at or below 400 ng per ml and who have already been treated with sorafenib. AFP is a biomarker that can be assessed through a blood tests, which Lilly officials say makes it much easier to determine treatment options for patients.
The approval comes after Lilly handed up results from a Phase 3 study which selected patients based on their AFP levels. Cyramza was previously approved, singly or in combination, for gastric, non-small cell lung, colorectal and hepatocellular cancers.
Upcoming Events
-
21Oct